The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis

ObjectiveIn December 2021, evolocumab and alirocumab were included in the National Reimbursement Drug List Negotiation (NRDLN), with implementation commencing in January 2022. This study aimed to evaluate the impact of the NRDLN policy on the clinical utilization of two novel lipid-lowering agents i...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Wan Tang, Wei Li, Anqi Zhang, Huanhuan Wu, Wei Lu, Yan Fan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-09-01
Subjects:	national reimbursement drug list negotiation interrupted time series analysis evolocumab alirocumab accessibility
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1612921/full